93. 原発性胆汁性胆管炎 [臨床試験数:230,薬物数:215(DrugBank:51),標的遺伝子数:34,標的パスウェイ数:107

Searched query = "Primary biliary cholangitis", "Primary biliary cirrhosis", "PBC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02376335October 201224/2/2015B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary CirrhosisB-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary CirrhosisFatigue;Primary Biliary CirrhosisBiological: Rituximab;Other: PlaceboNewcastle-upon-Tyne Hospitals NHS TrustNational Institute for Health Research, United Kingdom;Department of Health, United Kingdom;Newcastle UniversityCompleted18 YearsN/AAll71Phase 2United Kingdom
2EUCTR2012-000145-12-GB15/08/201204/07/2012Pilot study of Rituximab for the treatment of fatigue in PBCRituximab for the Treatment of Fatigue in Primary Biliary Cirrhosis (PBC) - RITPBC Study Severe fatigue in Primary Biliary Cirrhosis
MedDRA version: 18.0 Level: PT Classification code 10004661 Term: Biliary cirrhosis primary System Organ Class: 10019805 - Hepatobiliary disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
The Newcastle upon Tyne Hospitals NHS Foundation TrustNULLNot Recruiting Female: yes
Male: yes
58 Human pharmacology (Phase 1): no Therapeut1c exploratory (Phase 2): yes Therapeut1c conf1rmatory - (Phase 3): no Therapeut1c use (Phase 4): noUnited Kingdom
3NCT00364819January 200715/8/2006Initial Study of Rituximab to Treat Primary Biliary CirrhosisEffects of Rituximab (Rituxan) on B Cell and AMA Response in Patients With Primary Biliary CirrhosisPrimary Biliary CirrhosisDrug: rituximabUniversity of California, DavisGenentech, Inc.Completed18 Years65 YearsFemale6Phase 1/Phase 2United States